therapy, four went into complete remission for as long as six months.
The findings are preliminary, and the therapy remains experimental, the researchers pointed out.
But experts said the results are encouraging considering the outlook these AML patients faced before the trial. Their cancer had either failed to respond to standard chemotherapy or had come back, and they had run out of options.
“When you see this kind of response in these patients, it’s provocative,” said Dr. Todd Fehniger. He’s the study’s senior researcher and an associate professor of medicine at Washington University in St. Louis.
You May Also Like
But he also urged caution: The early phase trial was designed primarily to test the NK therapy’s safety. Larger, longer-term trials are
